Your browser is no longer supported. Please, upgrade your browser.
ATNM Actinium Pharmaceuticals, Inc. daily Stock Chart
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.22 Insider Own0.20% Shs Outstand121.72M Perf Week-42.59%
Market Cap37.73M Forward P/E- EPS next Y-0.08 Insider Trans- Shs Float117.58M Perf Month-43.64%
Income-23.70M PEG- EPS next Q-0.06 Inst Own12.50% Short Float1.66% Perf Quarter-32.05%
Sales- P/S- EPS this Y44.00% Inst Trans- Short Ratio2.34 Perf Half Y-60.11%
Book/sh0.08 P/B3.88 EPS next Y63.20% ROA-116.40% Target Price4.29 Perf Year-17.33%
Cash/sh0.11 P/C2.75 EPS next 5Y- ROE-159.10% 52W Range0.33 - 0.87 Perf YTD-19.90%
Dividend- P/FCF- EPS past 5Y14.00% ROI- 52W High-64.17% Beta2.57
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low-6.71% ATR0.06
Employees30 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)23.83 Volatility10.17% 9.79%
OptionableYes Debt/Eq0.02 EPS Q/Q14.40% Profit Margin- Rel Volume24.23 Prev Close0.45
ShortableYes LT Debt/Eq0.00 EarningsMar 28 AMC Payout- Avg Volume832.43K Price0.31
Recom1.80 SMA20-40.83% SMA50-44.27% SMA200-47.52% Volume20,172,700 Change-31.55%
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Apr-18-19 09:00AM  Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants PR Newswire -31.55%
Apr-17-19 04:01PM  Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants PR Newswire -9.44%
Apr-08-19 08:00AM  Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium PR Newswire
Apr-04-19 09:57AM  The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy Zacks
Apr-03-19 09:16AM  Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy Zacks
08:00AM  Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR PR Newswire
Apr-01-19 09:00AM  What Makes Actinium (ATNM) a New Buy Stock Zacks +25.00%
Mar-29-19 08:00AM  Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated PR Newswire
Mar-26-19 08:00AM  Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope PR Newswire
Mar-20-19 08:00AM  Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting PR Newswire
Mar-19-19 05:05PM  Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs PR Newswire
05:00PM  Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights PR Newswire
Mar-15-19 05:05PM  Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings PR Newswire +6.87%
08:00AM  Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference PR Newswire
Mar-07-19 12:15PM  What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.s (NYSEMKT:ATNM)? Simply Wall St.
Feb-25-19 02:20PM  4 Healthcare Stocks Looking To Kick Off A Strong Week ACCESSWIRE
08:00AM  Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial PR Newswire
Feb-21-19 08:00AM  Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy PR Newswire
Feb-15-19 07:40AM  Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-12-19 08:00AM  Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting PR Newswire
Feb-06-19 08:00AM  Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program PR Newswire
Feb-05-19 08:00AM  Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax PR Newswire
Feb-04-19 08:00AM  Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin PR Newswire +5.40%
Jan-29-19 08:00AM  Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th PR Newswire
Jan-25-19 08:00AM  Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference PR Newswire +10.26%
Jan-23-19 08:00AM  Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain PR Newswire
Jan-17-19 08:00AM  Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated PR Newswire +6.07%
Jan-16-19 08:00AM  Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies PR Newswire
Jan-03-19 08:00AM  Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase in San Francisco PR Newswire
Dec-21-18 02:08PM  How Does Investing In Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Impact The Volatility Of Your Portfolio? Simply Wall St.
Dec-04-18 08:00AM  Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting PR Newswire -5.93%
Dec-03-18 08:00AM  Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate PR Newswire
Nov-19-18 08:00AM  Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference PR Newswire -6.97%
Nov-05-18 08:00AM  Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference PR Newswire
Nov-01-18 09:01AM  Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data PR Newswire
Oct-30-18 05:05PM  Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax PR Newswire
Oct-26-18 08:00AM  Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update PR Newswire -7.78%
Oct-24-18 08:00AM  Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference PR Newswire -7.09%
Oct-22-18 09:30AM  Has Actinium Pharmaceuticals (ATNM) Outpaced Other Medical Stocks This Year? Zacks +5.01%
08:43AM  Do Options Traders Know Something About Actinium (ATNM) Stock We Don't? Zacks
08:04AM  Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update PR Newswire
Oct-19-18 08:10AM  Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-16-18 07:12AM  Top Ranked Momentum Stocks to Buy for October 16th Zacks
Oct-15-18 07:21AM  Top Ranked Momentum Stocks to Buy for October 15th Zacks
Oct-01-18 08:00AM  Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers PR Newswire
Sep-26-18 08:00AM  Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T PR Newswire
Sep-20-18 08:00AM  Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease PR Newswire
Sep-18-18 09:34AM  Should You Worry About The Actinium Pharmaceuticals Incs (NYSEMKT:ATNM) Shareholder Register? Simply Wall St.
08:00AM  Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space PR Newswire
Sep-06-18 08:00AM  Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations PR Newswire
Sep-05-18 06:37PM  Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions PR Newswire
Aug-14-18 04:05PM  Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting PR Newswire
Jul-17-18 05:30PM  Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning GlobeNewswire
Jul-09-18 04:15PM  Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients GlobeNewswire +6.81%
Jul-02-18 07:05AM  Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks ACCESSWIRE -7.81%
Jun-28-18 08:00AM  Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients GlobeNewswire
Jun-26-18 08:00AM  Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial GlobeNewswire +9.15%
Jun-25-18 04:15PM  Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting GlobeNewswire
Jun-13-18 08:00AM  Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M GlobeNewswire +5.09%
Jun-06-18 03:54PM  How Should You Think About Actinium Pharmaceuticals Incs (NYSEMKT:ATNM) Risks? Simply Wall St.
Jun-04-18 07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE
May-08-18 07:30AM  Actinium Pharmaceuticals to Present at 19th Annual Bioquity Europe Conference in Ghent, Belgium GlobeNewswire
May-01-18 07:30AM  Actinium Pharmaceuticals Appoints Dr. Jeffrey Chell, Bone Marrow Transplant Visionary and Chief Executive Officer Emeritus of Be The Match and National Marrow Donor Program, to its Board of Directors GlobeNewswire
Apr-18-18 07:30AM  Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development GlobeNewswire
Apr-11-18 07:30AM  Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting GlobeNewswire
Apr-02-18 07:30AM  Blog Exposure - Actinium Announces Collaboration with Astellas Pharma ACCESSWIRE
Mar-28-18 08:00AM  Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actiniums AWE Platform Technology GlobeNewswire
Mar-15-18 07:30AM  Actinium Pharmaceuticals to Present at 28th Annual Oppenheimer Healthcare Conference GlobeNewswire
Mar-14-18 07:30AM  Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs GlobeNewswire
Mar-13-18 07:30AM  Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML GlobeNewswire
Mar-07-18 07:30AM  Actinium Pharmaceuticals to Present at 30th Annual ROTH Conference GlobeNewswire
Mar-05-18 07:30AM  Actinium Announces $15.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering GlobeNewswire
Mar-01-18 07:30AM  Wired News Actinium Pharma Announced Activation of Sixteen Clinical Trial Sites in Phase-3 SIERRA Trial for Iomab-B ACCESSWIRE
Feb-28-18 07:30AM  Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations GlobeNewswire
Feb-27-18 07:30AM  Actinium Pharmaceuticals Announces Activation of Sixteenth Clinical Trial Site in the Pivotal Phase 3 SIERRA Trial for Iomab-B GlobeNewswire
Feb-26-18 09:53AM  Actinium Pharmaceuticals Reiterates Previously Announced Expiration Date of March 2, 2018 at 5:00 PM ET and Amendment to Pricing Terms of its Rights Offering GlobeNewswire -14.55%
Feb-22-18 07:30AM  Actinium Pharmaceuticals Announces Commencement of Rights Offering Subscription Period GlobeNewswire
Feb-20-18 07:30AM  Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations GlobeNewswire
Feb-12-18 04:15PM  Actinium Announces Submission of IND For Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML GlobeNewswire
07:30AM  Actinium Pharmaceuticals Reminds Investors of Todays Deadline to be a Shareholder of Record GlobeNewswire
Feb-08-18 08:00AM  Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation GlobeNewswire -9.25%
07:20AM  Wired News Actinium Pharma Reported Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients ACCESSWIRE
Feb-07-18 09:00AM  Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering GlobeNewswire
Feb-06-18 07:30AM  Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients GlobeNewswire
Feb-05-18 04:15PM  Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference GlobeNewswire
Feb-01-18 04:05PM  Actinium Pharmaceuticals Announces Rights Offering GlobeNewswire
07:30AM  Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product GlobeNewswire
Jan-25-18 08:00AM  Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018 GlobeNewswire
Jan-17-18 08:15AM  Market Trends Toward New Normal in FTD Companies, Acuity Brands, MINDBODY, Actinium Pharmaceuticals, XG Technology, and Aethlon Medical Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jan-09-18 08:43AM  PTC Therapeutics (PTCT) Jumps: Stock Rises 12.9% Zacks
Jan-08-18 11:07AM featured highlights include: Western Digital, Hecla Mining, Sphere 3D, Actinium Pharmaceuticals and Southern National Bancorp Zacks
07:30AM  Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Companys AWE Technology Platform and Research Programs GlobeNewswire
Jan-05-18 07:48AM  Beat the Market with Rising P/E Technique Zacks
Jan-03-18 07:30AM  Actinium Pharmaceuticals to Present at Biotech Showcase 2018 and Participate in Partnering Sessions GlobeNewswire
Dec-28-17 09:45AM  Actinium Posts Positive DMC View on Lomab-B Phase III Trial Zacks
Dec-27-17 09:00AM  Actinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial Continue GlobeNewswire
Dec-12-17 07:30AM  Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting GlobeNewswire -6.75%
Dec-11-17 04:15PM  Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M GlobeNewswire
06:30AM  Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-05-17 07:30AM  Actinium Pharmaceuticals Unveils Actimab-MDS and Planned Phase 2 Trial in Myelodysplastic Syndromes Targeted at Patients with High-Risk p53+ Genetic Mutations GlobeNewswire
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. The company has a collaboration with Astellas Pharma Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.